Relationship between HER2 gene status and selected potential biological features related to trastuzumab resistance and its influence on survival of breast cancer patients undergoing trastuzumab adjuvant treatment

References

• SlamonDJClarkGMWongSGLevinWJUllrichAMcGuireWLHuman breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogeneScience198723547851771823798106
   PubMed Web of Science ®Google Scholar
• DePHasmannMLeyland-JonesBMolecular determinants of trastuzumab efficacy: what is their clinical relevance?Cancer Treat Rev201339892593423562214
   PubMed Web of Science ®Google Scholar
• WolffACHammondMEHicksDGAmerican Society of Clinical Oncology; College of American PathologistsRecommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline updateJ Clin Oncol201331313997401324101045
   PubMed Web of Science ®Google Scholar
• CobleighMAVogelCLTripathyDMultinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic diseaseJ Clin Oncol19991792639264810561337
   PubMed Web of Science ®Google Scholar
• VogelCLCobleighMATripathyDEfficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancerJ Clin Oncol200220371972611821453
   PubMed Web of Science ®Google Scholar
• MukoharaTMechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancerCancer Sci201110211820825420
   PubMed Web of Science ®Google Scholar
• Luque-CabalMGarcía-TeijidoPFernández-PérezYSánchez-LorenzoLPalacio-VázquezIMechanisms behind the resistance to trastuzumab in HER2-amplified breast cancer and strategies to overcome itClin Med Insights Oncol201610Suppl 1213027042153
   PubMedGoogle Scholar
• XuQQPanBWangCJHER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysisOncotarget2016739635716358227566580
   PubMedGoogle Scholar
• LeeHJSeoANKimEJHER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancerAm J Clin Pathol2014142675576625389328
   PubMed Web of Science ®Google Scholar
• SingerCFTanYYFitzalFAustrian Breast and Colorectal Cancer Study GroupPathological complete response to neoadjuvant trastuzumab is dependent on HER2/CEP17 ratio in HER2-amplified early breast cancerClin Cancer Res201723143676368328143867
   PubMed Web of Science ®Google Scholar
• KimJWKimJHImSAHER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancerCancer Chemother Pharmacol201372110911523673443
   PubMed Web of Science ®Google Scholar
• FuchsEMKöstlerWJHorvatRHigh-level ERBB2 gene amplification is associated with a particularly short time-to-metastasis, but results in a high rate of complete response once trastuzumab-based therapy is offered in the metastatic settingInt J Cancer20131351224231
   Web of Science ®Google Scholar
• GiulianiRDurbecqVDi LeoAPhosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC)Eur J Cancer200743472573517251007
   PubMed Web of Science ®Google Scholar
• DowsettMProcterMMcCaskill-StevensWDisease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA TrialJ Clin Oncol200927182962296919364966
   PubMed Web of Science ®Google Scholar
• XuanQJiHTaoXXuYZhangQQuantitative assessment of HER2 amplification in HER2-positive breast cancer: its association with clinical outcomesBreast Cancer Res Treat2015150358158825762478
   PubMed Web of Science ®Google Scholar
• BorleyAMercerTMorganMImpact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer networkBr J Cancer201411082139214324691421
   PubMed Web of Science ®Google Scholar
• PerezEAReinholzMMHillmanDWHER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trialJ Clin Oncol201028284307431520697084
   PubMed Web of Science ®Google Scholar
• StockerAHilbersMLGauthierCHER2/CEP17 ratios and clinical outcome in HER2-positive early breast cancer undergoing trastuzumab-containing therapyPLoS One2016117e015917627463363
   PubMed Web of Science ®Google Scholar
• AdamczykANiemiecJJaneckaAPrognostic value of PIK3CA mutation status, PTEN and androgen receptor expression for metastasis-free survival in HER2-positive breast cancer patients treated with trastuzumab in adjuvant settingPol J Pathol201566213314126247526
   PubMed Web of Science ®Google Scholar
• WolffACHammondMESchwartzJNAmerican Society of Clinical Oncology; College of American PathologistsAmerican Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancerJ Clin Oncol200725111814517159189
   PubMed Web of Science ®Google Scholar
• TchrakianNFlanaganLHarfordJGannonJMQuinnCMNew ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancersVirchows Arch2016468220721126521061
   PubMed Web of Science ®Google Scholar
• PolóniaALeitãoDSchmittFApplication of the 2013 ASCO/CAP guideline and the SISH technique for HER2 testing of breast cancer selects more patients for anti-HER2 treatmentVirchows Arch2016468441742326754674
   PubMed Web of Science ®Google Scholar
• OwensMAHortenBCDa SilvaMMHER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissuesClin Breast Cancer200451636915140287
   PubMedGoogle Scholar
• PetroniSAddatiTMattioliECentromere 17 copy number alteration: negative prognostic factor in invasive breast cancer?Arch Pathol Lab Med20121369993100022938586
   PubMed Web of Science ®Google Scholar
• TsudaHAkiyamaFTerasakiHDetection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpressionCancer200192122965297411753973
   PubMed Web of Science ®Google Scholar
• LuohSWRamseyBHanlon NewellAHER-2 gene amplification in human breast cancer without concurrent HER-2 overexpressionSpringerplus2013238624102037
   PubMed Web of Science ®Google Scholar
• LoiSDafniUKarlisDEffects of estrogen receptor and human epidermal growth factor receptor-2 levels on the efficacy of trastuzumab: a secondary analysis of the HERA trialJAMA Oncol2016281040104727100299
   PubMed Web of Science ®Google Scholar
• KonecnyGPaulettiGPegramMQuantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancerJ Natl Cancer Inst200395214215312529347
   PubMed Web of Science ®Google Scholar
• PietrasRJArboledaJReeseDMHER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cellsOncogene19951012243524467784095
   PubMed Web of Science ®Google Scholar
• VargaZTubbsRRMochHConcomitant detection of HER2 protein and gene alterations by immunohistochemistry (IHC) and silver enhanced in situ hybridization (SISH) identifies HER2 positive breast cancer with and without gene amplificationPLoS One201498e10596125153153
   PubMed Web of Science ®Google Scholar
• PressMFSauterGBuyseMHER2 gene amplification testing by fluorescent in situ hybridization (FISH): comparison of the ASCO-College of American Pathologists Guidelines with FISH scores used for enrollment in Breast Cancer International Research Group clinical trialsJ Clin Oncol201634293518352827573653
   PubMed Web of Science ®Google Scholar
• PerezEABaehnerFLButlerSMThe relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831Breast Cancer Res201517113326429296
   PubMed Web of Science ®Google Scholar
• Lehmann-CheJAmira-BouhidelFTurpinEImmunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approachesBr J Cancer2011104111739174621540864
   PubMed Web of Science ®Google Scholar
• NgCKMartelottoLGGauthierAIntra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplificationGenome Biol20151610725994018
   PubMed Web of Science ®Google Scholar
• JaniszewskaMLiuLAlmendroVIn situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancerNat Genet201547101212121926301495
   PubMed Web of Science ®Google Scholar
• CameronDPiccart-GebhartMJGelberRDHerceptin Adjuvant (HERA) Trial Study Team11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trialLancet2017389100751195120528215665
   PubMed Web of Science ®Google Scholar
• GuiuSGauthierMCoudertBPathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancerBr J Cancer201010391335134220978512
   PubMed Web of Science ®Google Scholar
• GulloGBettioDZuradelliMLevel of HER2/neu amplification in primary tumours and metastases in HER2-positive breast cancer and survival after trastuzumab therapyBreast201322219019323473771
   PubMed Web of Science ®Google Scholar
• ParkYHJungHAChoiMKRole of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatmentBr J Cancer2014110238439124346286
   PubMed Web of Science ®Google Scholar
• OcanaAVera-BadilloFSerugaBTempletonAPandiellaAAmirEHER3 overexpression and survival in solid tumors: a meta-analysisJ Natl Cancer Inst2013105426627323221996
   PubMedGoogle Scholar
• ZaczekABrandtBBielawskiKPThe diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approachesHistol Histopathol20052031005101515944951
   PubMed Web of Science ®Google Scholar
• SpearsMTaylorKJMunroAFIn situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancerBreast Cancer Res Treat2012132246347021638049
   PubMed Web of Science ®Google Scholar
• ZagouriFSergentanisTNChrysikosDPertuzumab in breast cancer: a systematic reviewClin Breast Cancer201313531532423810292
   PubMed Web of Science ®Google Scholar
• von MinckwitzGProcterMde AzambujaEAPHINITY Steering Committee and InvestigatorsAdjuvant pertuzumab and trastuzumab in early HER2-positive breast cancerN Engl J Med2017377212213128581356
   PubMed Web of Science ®Google Scholar
• GerratanaLBonottoMBozzaCPertuzumab and breast cancer: another piece in the anti-HER2 puzzleExpert Opin Biol Ther201717336537428092723
   PubMed Web of Science ®Google Scholar